Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-02-28
2009-11-24
Kifle, Bruck (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C540S456000
Reexamination Certificate
active
07622477
ABSTRACT:
Isomers and 42-epimers of rapamycin alkyl ether analogs and pharmaceutically acceptable salts or prodrugs thereof, are immunomodulatory agents and are useful in the treatment of restenosis and immune and autoimmune diseases. Also disclosed are cancer-, fungal growth-, restenosis-, post-transplant tissue rejection- and immune- and autoimmune disease-inhibiting compositions and a method of inhibiting cancer, fungal growth, restenosis, post-transplant tissue rejection, and immune and autoimmune disease in a mammal. One particular preferred application of such isomers and 42-epimers of rapamycin alkyl ether analogs is in medicated devices and local vascular delivery wherein the stability and lipid solubility and subsequently diffusion through tissue and cell membranes are essential to the success of rapamycin containing combination devices.
REFERENCES:
patent: 3929992 (1975-12-01), Sehgal et al.
patent: 3993749 (1976-11-01), Sehgal et al.
patent: 4316885 (1982-02-01), Rakhit
patent: 4401653 (1983-08-01), Eng
patent: 4650803 (1987-03-01), Stella et al.
patent: 4885171 (1989-12-01), Surendra et al.
patent: 5023262 (1991-06-01), Caufield et al.
patent: 5120725 (1992-06-01), Kao et al.
patent: 5120727 (1992-06-01), Kao et al.
patent: 5120842 (1992-06-01), Failli et al.
patent: 5177203 (1993-01-01), Failli et al.
patent: 5221740 (1993-06-01), Hughes
patent: 5233036 (1993-08-01), Hughes
patent: 5258389 (1993-11-01), Goulet et al.
patent: 5457111 (1995-10-01), Luly et al.
patent: 5525610 (1996-06-01), Caufield et al.
patent: 5672605 (1997-09-01), Or et al.
patent: 6015815 (2000-01-01), Mollison
patent: 6227983 (2001-05-01), Yang
patent: 6329386 (2001-12-01), Mollison
patent: 7074804 (2006-07-01), Zhu et al.
patent: 2005/0014777 (2005-01-01), Zhu et al.
patent: 2005/0038505 (2005-02-01), Shulze et al.
patent: 2005/0131008 (2005-06-01), Betts et al.
patent: 184162 (1986-06-01), None
patent: 467606 (1992-01-01), None
patent: WO 92/05179 (1992-04-01), None
patent: WO 94/09010 (1994-04-01), None
patent: WO 98/09972 (1998-03-01), None
patent: WO 2006/096325 (2006-09-01), None
Hughes, P. et al. “The Isolation, Synthesis andCharacterization of An Isomeric Form of Rapamycin” Tetrahedron Letters 1992 U.K. vol. 33, No. 33, 1992 p. 4739-4742.
European Search Report dated Jun. 28, 2007 for Application No. 0725709.8-1211.
Bierer, B.E., et al. “The Effect of the Immunosupprssant FK-06 on Alternate Pathways of T Cell Activation”, Eur. J. Immunol. 1991, 439-445.
Brown, E.J., et al. “A Mammalian Protein Targeted by G1-Arreting Rapamycin-Receptor Complex”, Letters to Nature, vol. 369, p. 756.
Dumont, F.J., et al. “The Immunosuppressive Macrolides FK-506 and Rapamycin Act as Reciprocal Antagonists in Murine T Cells”, Journal of Immunology, vol. 144, No. 4, 1990, pp. 1418-1424.
Fretz, H., et al. Rapamycin andFK506 Binding Proteins (Immunophilins), J. Am. Chem. Soc. 1991, vol. 113, pp. 1409-1411.
Hayward, C.J., et al. “Total Synthesis of Rapamycin via a Novel Titanium-Mediated Aldo Macrocycliation Reaction”, J. Am. Chem. Soc. 1993, ol. 115, pp. 9345-9346.
Nicolaou, K.C., et al. “Total Synthesis of Rapamycin”, J. Am. Chem. Soc. 1993, vol. 115, pp. 4419-4420.
Paiva, N.L., et al. “Incorporation of Acetate, Propionae, ad Methionine Into Rapamycin by Streptomyces Hygrosscopicus”, Journal of Natural Products, vol. 54, No. 1, pp. 167-177, 1991.
Romo, D., et al. “Total Synthesis of (−) Rapamycin Using an Evans-ischenko Fragment Coupling”, J. Am. Chem. Soc. 1993,vol. 115, pp. 7906-7907.
Sabatini, D.M, et al. “Raft1: A Mammalian Protein That Binds to FKBP 12 in a Rapamycin-Dependent Fashion and is Homologous to Yeast TORs”, Cell, vol. 78, 1994, pp. 35-43.
Siekierka, J.J, et al. “A Cyosolic Binding Protein for the Immunosuppressant FK506 Has Peptidyl-Propyl Isomerase Activity but is Distinct from Cyclophilin”, Letters to Nature, vol. 341, 1989, p. 755.
Baker, H.A., et al., J. Antibiot., Rapamycin,A New Antifungal Antibiotic . . .31, 539-545, 1978.
Bierer, B.E., et al., J. Immunol.,The effect of the immunosuppressant FK-506 on alternate pathways of T cell activation, 21, 439-445, 1991.
Brown, E.J., et al., Nature,A mammalian protein targeted by G1-arresting rapamycin-receptor complex, 369, 756-758, 1994.
Bunchman, E.T. et al., Transplantation Proceed.,Smooth Muscle Cell Proliferation by Conditioned Media From Cyclosporine-Treated Endothelial. . . 23 967-968, 1991.
Danishefsky, S.J., J. Am. Chem. Soc.,Total synthesis of rapamycin via a novel titanium-mediated aldol macrocyclization reaction. . . , 115, 9345-9346, 1993.
Dumont, F.J., et al., J. Immunol.,The Immunosuppressive Macrolides FK-506 and Rapamycin Act As Reciprocal Antagonists. . . , 144, 1418-1424, No. 4, 1990.
Fretz, H., et al., J. Am. Chem. Soc.,Rapamycin and FK506 binding proteins(immunophilins), 113 (4), 1409-1411, 1991.
Harding, M.W., et al., Nature,A receptor for the immuno-suppressant FK506 is a cis-trans peptidyl-prolyl isomerase, 1989, 341, 758-560, 1989. (Same as Schreiber, S.L., Nature reference).
Higuchi, T., Pro-drugs as Novel Delivery Systems, vol. 14 of a.C.S. Symposium Series, 1975.
Martel, R. et al., Can. J. Physiol. Pharmacol.,Inhibition of the immune response by rapamycin, a new antifungal antibiotic, 55(1), 48-51, 1977.
Morris, R. Med Sci. Res., Letters to the Editor-Identification of a new pharmacologic action for an old compound, 17, 877-878, 1989.
Nicolaou, K.C. et al., J. Am. Chem. Soc.,Total synthesis of rapamycin, 115 (10), 1993.
Pavia, N.L., J. Natural Products,Incorporation of Acetate, Propionate, and Methionine Into Rapamycin by. . . , 54(1), 167-177, 1991.
Prescott, Ed.,Methods in Cell Biology, vol. XIV, Academic Press, NY, NY p. 33 et seq., 1976.
Roche, Edward B.,Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987.
Sabatini, D.M. et al., Cell,RAFT1: A Mammalian Protein That Binds to FKBP12 in a Rapamycin-Dependent Fashion and is Homologous to Yeast,,,, 78, 35-43, 1994.
Schreiber, S.L. J Am Chem. Soc.,Total Synthesis of(—)-Rapamycin Using an Evans-Tishchenko Fragment Coupling, 115, 7906-7907, 1993.
Sehgal, S.N., et al., J. Antibiot. (Tokyo),Rapamycin(AY-22,989),A New Antifungal Antibiotic. . . , 28(10), 727, 1975.
Siekierka, J.J. et al., Nature,A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct. . . , 341, 755-757, 1989.
Shichri, M. et al., J. Clin. Invest.Endothelin-1 is an Autocrine/Paracrine Growth Factor for Human Cancer Cell Lines, 87 1867-1871, 1991.
Strauch, M.J., Federation of American Societies for Experimental Biology,FK506 and Rapamycin Inhibit Murine T Cell Activation. . . , 3, 3411, 1989.
Transplantation Reviews, (Morris),Rapamycins: Antifungal, Antitumor, Antiproliferative, and Immunosuppressive Macrolides, 6, 39-87, 1992.
Vezina, C., et al., J. Antibiot.,(Tokyo),Rapamycin(AY-22, 989)A New Antifungal Antibiotic. . . , 28, (10) 721, 1975.
Yamagishi, et al., Biochem. Biophys. Res. Comm.,Endothelin 1 Mediates Cell-Dependent Proliferation of. . . , 191 840-846, 1993.
S.N. Sehgal et al., J. Antibiot.,Demethoxyrapamycin(AY-24,668),A New Antifungal Antiotic, 36(4), 351, 1983.
Cordis Corporation
Kifle Bruck
LandOfFree
Isomers and 42-epimers of rapamycin alkyl ether analogs,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Isomers and 42-epimers of rapamycin alkyl ether analogs,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Isomers and 42-epimers of rapamycin alkyl ether analogs,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4054997